|
Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
|
|||||||||||
| Features of this market research: |
Identify the key trends that are driving and resisting the growth of the pharmaceutical market in key developing countries Understand the macroeconomic factors and healthcare system characteristics impacting the pharmaceutical market in the analyzed countries Gain insight into current market dynamics and opportunities and challenges for foreign companies wishing to enter these emerging markets. 407 pages | |||||||||||
| About this market survey: |
With dwindling growth rates observed in the major developed markets many pharmaceutical companies are turning towards emerging market countries in order to sustain their revenue growth. While some cou.....
With dwindling growth rates observed in the major developed markets many pharmaceutical companies are turning towards emerging market countries in order to sustain their revenue growth. While some countries, with double digit growth rates present tremendous opportunities, there are also many obstacles that need to be overcome. Report Highlights Fast economic growth, increasing economic and political stability coupled with tremendous patient potential and increased Westernization of lifestyle present new opportunities for global pharmaceutical companies. Despite problematic intellectual property protection high market potential is attracting most multinational pharmaceutical companies. Healthcare system characteristics differ greatly between different emerging market countries. Greater state participation in healthcare provision is observed in all markets although growing disposable income and out-of-pocket expenditure are contributing to market growth. The changing medical needs of the emerging countries are favoring multinational companies: sales of anti-infective agents are slowing down and cancer drugs, immunomodulatory and respiratory drugs among others are growing at fast rates. With increasing purchasing power consumer preference for expensive new treatments is growing. [Fade out the market survey infos] |
|||||||||||
|
CHAPTER 1 EXECUTIVE SUMMARY 4 Scope of the report 4 IMS caveat 4 Scorecard for analyzed countries 5 Patient potential in key emerging markets 6 Socioeconomic trends and business environment in key emerging markets 6 Health system dynamics 6 Pricing and reimbursement environment 7 Regulatory environment in key emerging markets-uncertainties exist but do not present major hurdles 8 Pharmaceutical market dynamics 8 CHAPTER 2 THE PHARMACEUTICAL MARKET IN BRAZIL 13 Tight pricing control is a downside but the overall environment and healthcare provision is improving 13 Demographic trends in Brazil 15 Disease burden is similar to the Western countries 17 Socioeconomic environment in Brazil - a land of inequality 18 Political climate is stable 18 Brazilian economy is growing at a moderate but steady level 19 Regional differences are great 21 Mercosur-the common market of South America 21 There is an abundant semi-skilled and unskilled workforce but the educational level is low 22 Business environment in Brazil-regulation and bureaucracy are considerable 22 Business entities 22 Taxation system is complex 23 Foreign direct investment in Brazil is growing 24 Importation is costly and laborious but export is incentivized 25 The healthcare system in Brazil is based on a public-private mix 26 Healthcare expenditure in Brazil 27 The public sector - the Unified Health System (SUS) 27 The private sector is restricted to the rich 28 After years of focus on hospital care, primary care is now predominant 30 Regulatory issues in Brazil 32 Intellectual property protection: long delays exist 32 Compulsory licenses on HIV/AIDS drugs were used only as a threat until May 2007 33 Registration of drugs-regulatory requirements are tightening 34 Imported pharmaceuticals have to be registered with ANVISA 36 Counterfeit drugs present a problem but a crackdown has started 36 Pricing and reimbursement of drugs in Brazil 37 Multiple mechanisms ensure tight price control on pharmaceuticals 37 Prices of marketed pharmaceuticals are controlled through price freezes and increases 38 Anti-retroviral drugs are priced low 40 Reimbursement is limited but is expected to improve 41 Patients are turning to courts to ensure they receive new treatments 45 Pharmaceutical market dynamics in Brazil 47 Distribution: a highly fragmented market 49 Brazil has a high number of pharmacies 50 Top manufacturers on the Brazilian retail market 51 Top ATC groups by sales value on the Brazilian retail pharmaceutical market 52 Top brands on the Brazilian retail market 54 Hospital sales of pharmaceuticals in Brazil 55 Advertising, marketing and sales of drugs 56 Major foreign pharmaceutical companies in Brazil 56 Sanofi-Aventis 57 Novartis 57 Bayer Schering 57 Pfizer 58 Boehringer-Ingelheim 58 It is difficult for multinational companies to enter the generics market 59 Major domestic pharmaceutical companies in Brazil 59 The generics market is dominated by a small number of leading companies 59 EMS 60 Medley 60 Eurofarma 61 Group Castro Marques (Biolab) 61 Ache Biosintetica 61 Drug manufacturing in Brazil 62 Multinational companies are ramping up export of drugs from Brazil but domestic companies are lagging behind 63 State-owned drug manufacturing is focused on antiretroviral drugs for HIV/AIDS 63 Investment in R&D in Brazil is growing 65 Phytopharmaceuticals-a new opportunity for Brazilian companies? 66 Clinical trials in Brazil 66 CHAPTER 3 THE PHARMACEUTICAL MARKET IN RUSSIA 68 The new reimbursement system and growing out-of-pocket spend have resulted in fast growth of the Russian pharmaceutical market 68 Demographic trends in Russia 71 Basic facts 71 Life expectancy is surprisingly low 71 Ageing and depopulation are resulting from declining birth rates 72 Disease burden in Russia 73 Socioeconomic environment in Russia 74 Political climate in Russia 74 Russia remains a centralized country with the center of power in Moscow 74 Economic environment in Russia: GDP and disposable income are growing 75 The Russian economy is trying to break away from overdependence on natural resources and is diversifying 76 Large regional differences exist 76 Accession to WTO is expected to bring positive changes 77 The labor market in Russia 78 The population is highly educated but the output is low 78 Looming labor shortage 78 Business environment in Russia-corruption and lack of transparency create difficulties 79 Foreign direct investment in Russia is mostly in the natural resource industry 79 Corruption is widespread 80 Excessive bureaucracy-red tape 80 Registration of a legal entity in Russia is a long and costly procedure 80 Taxation differs for foreign companies 81 Pharmaceuticals are subject to a reduced VAT rate of 10% 82 Customs duties are slowly becoming in line with the WTO 82 Healthcare system in Russia 84 Mandatory health insurance was introduced in 1991 85 Certain diseases have become a priority of the Russian government 87 The healthcare reform of 1991 signaled the privatization of healthcare 88 Healthcare expenditure is below the level of Western EU countries 89 Increased funding for healthcare is one of the priorities of the government 91 Primary versus hospital healthcare in Russia-focus on hospital care 91 'Under the table' expenditure is high in Russia 92 Access to healthcare is especially problematic for the poor population 93 Companies offering private health insurance are scarce and focus on the top end of the market 93 Regulatory issues in Russia 94 Intellectual property protection-several key issues remain unresolved 94 Patents ( insufficient enforceability of patent laws is a problem 94 Data exclusivity remains an unresolved issue 95 Drug counterfeiting in Russia 96 Registration of drugs in Russia 97 Certification of drugs is cumbersome but is used to detect counterfeit drugs 98 A large proportion of drugs are sold without prescription 99 Pricing and reimbursement of drugs in Russia 100 Pricing of drugs-few restrictions exist 100 Reimbursement-federal and regional lists exist 101 Certain drugs used in hospitals are funded by regional health budgets 102 Introduction of the federal reimbursement system DLO was a major change 102 The DLO program ( growing pains? 103 Drug price cuts and changes to the reimbursement list failed to keep DLO spending within the allocated budget 105 Insufficient planning for demand is putting a strain on the DLO program 107 State is becoming a bigger purchaser of drugs 108 The future of DLO program 108 DLO will be split into two programs in 2008 110 Pharmaceutical market dynamics in Russia 111 The distribution sector is fragmented but is consolidating 112 Foreign investment in the sector is increasing 113 The pharmacy networks sector is fragmented 114 Global pharma lead the Russian pharmaceutical market by sales value 117 Generics dominate the market in volume terms but account for only a fraction of the sales value 118 The retail market segment is growing at a steady rate 119 Top brands in the retail market segment in Russia 119 Top ATC groups by sales in the retail sector in Russia 121 Top manufacturers on the Russian retail market 123 The hospital market segment in Russia 125 Multinational companies dominate the hospital segment 125 Systemic antibacterials are the best selling therapeutic class 127 Consumption of expensive medicines is increasing in the hospital segment 128 The DLO program is one of the major growth drivers of the Russian pharmaceutical market but faces stagnation 130 Antineoplastic and immunomodulating agents were the best selling group in the DLO program in 2006 131 DLO has failed to increase the share of domestic producers and foreign manufacturers dominate 133 The top brands list in the DLO segment in 2006 is dominated by foreign brands 136 The establishment of the DLO drove the growth of the oncology sector 137 The DLO segment faces stagnation in 2007 139 Drugs can be imported into Russia through different channels 140 Top ATC groups of imported drugs 144 Top imported brands in Russia 145 Top foreign manufacturers by sales of imported drugs 147 The Russian pharmaceutical market will continue to grow 148 Export of pharmaceuticals from Russia is low 148 Launch, marketing and branding in Russia 149 Branding is important in Russia 149 Advertising of pharmaceuticals in Russia 150 Merck's co-marketing deal with Otechestvennie Lekarstva ( a first of its kind 151 Innovative drugs have the best market potential in Russia 151 Market entry strategies: acquiring a domestic producer? 151 Major foreign pharmaceutical companies on the Russian market 152 Sanofi-Aventis is the top foreign pharmaceutical company in Russia 152 Novartis's presence in Russia is growing 152 Servier 152 Roche 153 Gedeon Richter 153 Nycomed 154 Eli Lilly 154 Novo Nordisk 154 Bayer Schering 155 Actavis has strengthened its position in the Russian market through the acquisition of ZIO Zdorovie 155 Stada has increased its presence in the Russian market through three different entities 156 Major domestic pharmaceutical companies on the Russian market 156 Pharmstandard 159 Veropharm 159 Domestic producers will grow 160 Innovation is lagging behind the West 160 Manufacturing drugs in Russia 161 Clinical trials in Russia: a growing opportunity 162 CHAPTER 4 THE PHARMACEUTICAL MARKET IN INDIA 166 Improved patent protection environment fails to deliver on its promise but economic growth keeps the potential alive 166 Demographic trends in India: a trend toward ageing and urban population growth 169 Disease burden in India 170 Socioeconomic environment in India 172 Political climate in India - open to economic liberalization 172 Economic growth is steady and is concentrated in mid-sized and small urban centers 173 Poverty is declining for the first time since independence 174 Middle class income population is booming 175 Inadequate infrastructure is a major obstacle to faster growth 176 India is a member of the World Trade Organization 177 India has a high number of educated scientists 178 Business environment in India 178 India is opening up to Foreign Direct Investment 178 Legal entities in India 179 Corporate taxes in India are high but R&D incentives are given 180 Indirect taxes are very high in India and create a barrier for foreign companies 181 The central excise duty charging system was changed in 2005 181 Value added tax (VAT) was introduced in 2005 in India 182 Import tariffs are high in India 183 Export is encouraged through subsidies and special economic zones 183 Transparency and corruption in India 184 Healthcare system in India 184 Public health expenditure is low in India 185 Alternative medicine-AYUSH 186 Only a small fraction of the population has social security or private health insurance 188 Access to healthcare is poor especially in rural regions 190 Public health programs in India 192 Regulatory issues in India 193 Intellectual property protection in India is insufficient 193 Case study: Glivec was refused patent protection on the basis that incremental innovation is not patentable 194 Case study: AstraZeneca's patent application for Iressa was also rejected 195 Pfizer's maraviroc patent was granted - a change of tide for IP environment 196 India is benefiting from compulsory licenses for HIV/AIDS drugs in other countries 196 India is a major source of counterfeit drugs 197 Registration of drugs in India is straightforward 197 Importation of pharmaceuticals into India 200 Pricing and reimbursement of drugs in India 201 Control on drug pricing is getting tighter and is threatening to reduce the growth of the Indian market 201 Prices of certain pharmaceuticals in India are subject to price controls 201 Prices of drugs not subject to price control are being increasingly monitored and capped 204 Only a small number of drugs in India are reimbursed 205 Pharmaceutical market dynamics in India 205 The distribution sector in India is highly fragmented 206 Retail pharmacy chains are starting to appear 208 Top manufacturers on the Indian retail market-domestic companies dominate 209 Anti-infectives and gastrointestinal drugs hold almost 50% of the total market 211 Top brands on the Indian pharmaceutical market 214 Export of drugs from India is growing 215 Major foreign pharmaceutical companies in India 215 GlaxoSmithKline 216 Sanofi-Aventis 217 Abbott Laboratories 218 Pfizer 218 Major domestic pharmaceutical companies in India 219 Ranbaxy 219 Cipla 220 Nicholas Piramal 220 Zydus Cadila 221 Sun Pharma 221 Alkem Laboratories 222 Lupin 222 Dr Reddy's 222 India is a major hub of drug manufacturing activity 223 India is developing its capacity for development and manufacturing of biosimilars 224 R&D activities are increasing in India 225 Clinical trials in India - a growing opportunity 227 CHAPTER 5 THE PHARMACEUTICAL MARKET IN CHINA 231 A growing economy is fuelling demand and its R&D potential is attracting investment 231 Demographic trends-the world's most populous country is ageing 233 Disease burden in China 234 Socioeconomic environment in China 235 Political climate-stable and supporting economic growth 235 China's economy continues to grow but remains over-reliant on exports 236 Fast economic growth has fueled China's energy demand 238 China's middle class is growing 238 China - a good education system 239 Business environment in China 239 Foreign direct investment is contributing to economic growth 239 Business entities in China 240 Taxation system in China 240 Corruption is widespread 241 The difference between Chinese and Western cultures and the language barrier are a difficulty 241 Healthcare system in China 241 Healthcare expenditure-growing but insufficient 242 Growing out-of-pocket spend is the main contributor to the rising healthcare expenditure 244 Healthcare reforms have resulted in lower healthcare utilization 244 Access to healthcare services is difficult and discriminatory against the poor and the rural population 245 The density of healthcare workers is low and the hospital facilities are in a great need of an overhaul 246 Health insurance coverage is increasing in both urban and rural areas but is insufficient 248 The introduction of the urban employee Basic Medical Insurance System has improved healthcare coverage in cities 248 Rural health insurance coverage is increasing but the benefits are insufficient 249 The unemployed may be offered a very basic health insurance 250 Traditional Chinese Medicine still plays a role in Chinese healthcare 250 Regulatory issues in China-an improving environment 251 Intellectual property protection-improving but still a way to go 251 New drug regulations have failed to improve the IP protection and to satisfy the global pharmaceutical industry 254 Compulsory license provision in China? 255 Counterfeit drugs represent a particular threat 255 Registration of drugs in China is a complex process 256 Priority review procedures have been put in place to tackle health crises 258 China has resorted to drastic measures to improve its safety record 259 Pressure from export partners is forcing China to introduce practical measures to improve safety record 260 Obtaining import drug licenses is a long and costly process 261 Traditional Chinese Medicine is not tightly regulated 261 Pricing and reimbursement of drugs in China 262 Price cuts of reimbursable drugs threaten to reduce profit margins of manufacturers 262 In order to reduce the healthcare cost burden for patients the government is imposing heavy price cuts 263 Prices of drugs sold in hospitals are over-inflated 264 Reimbursement is negotiated at local level 264 Pharmaceutical Catalog classification 265 Pharmaceutical market dynamics in China 267 The distribution system in China is complex 269 Sales of drugs through retail pharmacies are encouraged 270 Several large multinational companies are among the top drug manufacturers in China 271 Top ATC groups in China-anti-infectives remain at the top but their growth is slowing down 272 Top products on the Chinese hospital market 276 Major foreign pharmaceutical companies in China 278 Pfizer 278 AstraZeneca 278 Bayer Schering 279 Roche 280 Novartis 280 Sanofi-Aventis 281 GlaxoSmithKline 282 Major domestic pharmaceutical companies in China 283 Yangtze River Pharmaceutical Group 283 Jiangsu Hengrui Medicine Company 283 The Harbin Pharmaceutical Group 284 Drug manufacturing in China-GMP is improving but IP protection is insufficient for Western manufacturers 285 Several Chinese biotechnology companies already have biosimilars products on the Chinese market 286 Many multinational companies have opened R&D centers in China 287 Clinical trials in China - international interest is high 290 CHAPTER 6 THE PHARMACEUTICAL MARKET IN TURKEY 293 Low drug prices limit the market potential but the overall environment is improving 293 Demographic trends in Turkey 296 Disease burden in Turkey 297 Socioeconomic environment in Turkey 298 Political climate-the new government supports foreign investment in Turkey 298 Desired accession to the EU is a stimulant for economic growth 299 Turkey is a member of the WTO and has entered the Customs Union with the EU 300 Labor market in Turkey-lack of educated workforce 300 A large working age population 300 Educational level is low compared to the West 301 Business environment in Turkey 301 Foreign direct investment is low but is growing 301 Legal corporate entities in Turkey 302 Taxation is becoming investor-friendly 302 Turkey is in Customs Union with the EU 303 Foreign trade zones and free ports have special customs treatment and tax advantages 303 Corruption is present but the government is fighting against it 304 Healthcare system in Turkey - universal healthcare coverage is on its way 304 Access to healthcare is poor in rural regions 306 The Health Transformation Program is reforming healthcare and driving the growth of the pharmaceuticals sector 307 Primary and family care is important for provinces with traditionally poor access to healthcare 308 Private health insurance accounts for a very small percentage of the population 308 Expenditure on pharmaceuticals accounts for a high proportion of the healthcare spend 309 Regulatory issues in Turkey 310 IP and data exclusivity in Turkey-improved but still a way to go 310 Turkey is a source of counterfeit drugs 311 Registration and importation of drugs in Turkey 312 Pricing and reimbursement of drugs in Turkey 314 Reimbursement is available but criteria and decisions are not transparent 314 There is no rationalization of drug but may be introduced 315 Lack of transparency is a problem 316 Tight price controls have resulted in price decreases 316 Pharmaceutical market dynamics-tight pricing controls are stumping growth 318 Distribution is dominated by several large companies 320 Retail pharmacy chains are not permitted 321 Top ATC groups by sales value in Turkey 321 The top brands list in Turkey is dominated by foreign products 324 The top manufacturers list is dominated by foreign companies 325 Imported versus local drugs 327 Major foreign pharmaceutical companies in Turkey 327 Novartis 327 Sanofi-Aventis 327 Roche 328 GlaxoSmithKline 328 Pfizer 328 Bayer-Schering 329 Eli Lilly 329 Major domestic pharmaceutical companies in Turkey 329 Abdi Ibrahim 330 Zentiva has acquired a stake in Eczacibasi 330 Bilim Pharmaceuticals 330 Actavis acquired Turkey's Fako 331 Drug manufacturing in Turkey-an unexploited opportunity? 331 Export of pharmaceuticals from Turkey is low 332 Conducting clinical trials in Turkey 333 Registration of clinical studies-approval times may be shortened 334 Local CRO industry is starting to emerge 335 CHAPTER 7 BIBLIOGRAPHY 336 Publications and online articles 336 Conference literature 361 Datamonitor resources 361 Websites 361 Exchange rates 362 Suggested reading 363 APPENDIX 365 Russian Pharmaceutical Market: additional data 365 Domestic manufacturers on the Russian market 367 Retail market segment in Russia 367 Top 20 drug manufacturers in the retail segment 368 Top brands in the Russian retail market in 2006 369 The hospital market in Russia 369 Top manufacturers 370 Top brands in the hospital segment 371 The DLO market segment in Russia 372 Top manufacturers in the DLO segment 372 Top brands in the DLO segment 374 IMS Health sales data for the Russian pharmaceutical market 376 Top manufacturers on the Russian market 376 Top brands in Russia 377 Top ATC groups in Russia 378 IMS Health's MIDAS sales data audit 379 Glossary 383 [Fade out table of contents] |
||||||||||||
|
Table 1: Scorecard for the pharmaceutical markets in Brazil, Russia, India, China and Turkey 5 Table 2: Key demographic indicators for Brazil, 2005 16 Table 3: Top mortality causes in Brazil, 2002 17 Table 4: Brazil's average annual growth rate of GDP and exports (%), 1986-2010 20 Table 5: Key economic indicators for Brazil, 1986-2006 20 Table 6: Healthcare expenditure indicators in Brazil, 2004 27 Table 7: Density of healthcare workers and hospital capacity in Brazil, 2000 31 Table 8: Growth of the Brazilian pharmaceutical market by volume (%), 2003-06 39 Table 9: Branded generics dominate the Brazilian pharmaceutical market, 2006 48 Table 10: Brazil - average cost of units sold, 2003-06 49 Table 11: Top 15 Drug manufacturers in Brazil, 2006 51 Table 12: Segmentation of the Brazilian retail pharmaceutical market by ATC group sales value, 2006 52 Table 13: Top 15 brands in Brazil, 2006 54 Table 14: Key demographic indicators for Russia, 2004-2006 71 Table 15: Life expectancy and healthy life expectancy in Russia compared to the seven major markets, 2002 and 2005 72 Table 16: Top causes of mortality in Russia, 2002 73 Table 17: Russia is experiencing a steady growth in GDP, 2001-06 75 Table 18: Disposable income is also growing in Russia, 2002-05 76 Table 19: Healthcare expenditure in Russia, 2004 and 2005 90 Table 20: Hospital and healthcare capacity in Russia, 2003 92 Table 21: Top 20 pharmacy networks in Russia, 2006 116 Table 22: Top 20 drug manufacturers by sales value in the Russian pharmaceutical market, 2005 and 2006 118 Table 23: Top 25 brands by pharmacy sales value on the Russian market, 2006 120 Table 24: Sales structure by ATC group on the retail market, 2006 121 Table 25: Top 15 ATC2 groups by pharmacy sales value in Russia, 2006 123 Table 26: Top 25 manufacturers in the retail segment of the Russian market by value, 2006 124 Table 27: Top 25 manufacturers in the hospital segment in Russia, 2006 126 Table 28: Sales within the hospital segment by ATC group, 2006 127 Table 29: Top 25 products by hospital sales in Russia, 2006 129 Table 30: Sales structure by ATC groups of the DLO market, 2006 131 Table 31: Top 15 ATC1 groups in the DLO segment according to Pharmexpert, 2006 132 Table 32: Top 25 manufacturers within the DLO segment in Russian by value, 2006 134 Table 33: Top 25 brands in the DLO segment in 2006 136 Table 34: Top 10 oncology products in Russia, January-September 2006 138 Table 35: Top 10 manufacturers in the oncology segment in Russia, January-September 2006 139 Table 36: Shares in import value of different groups of drug importers in Russia, 2005 and 2006 141 Table 37: Top 10 representatives of foreign manufacturers by drugs import value, 2006 142 Table 38: Top 25 importers by import value in 2006 143 Table 39: Top 15 ATC2 groups of imported drugs to Russia by value, 2006 144 Table 40: Top 25 drugs imported in Russia by sales value, , 2006 146 Table 41: Top 25 foreign drug manufacturers by sales value of their imported drugs regardless of the import route, 2006 147 Table 42: Top 10 domestic manufacturers in Russia according to Pharmexpert, 2006 158 Table 43: Key demographic indicators for India 169 Table 44: Top 10 causes of mortality in India, 2002 171 Table 45: Key economic indicators for India, 2003-06 173 Table 46: Public healthcare expenditure indicators, 2004 185 Table 47: Traditional and indigenous systems of medicine in India 187 Table 48: Types of medical centers in the Indian public health sector 191 Table 49: Density of healthcare workers in India is extremely low 192 Table 50: Top 25 drug manufacturers in India, 2006 210 Table 51: Market segmentation in India according to ATC groups 211 Table 52: Top 15 brands on the Indian retail market, 2006 214 Table 53: Export of pharmaceuticals from India is growing, 2001-02-2006-07 215 Table 54: Recent R&D deals between Indian and multinational companies 227 Table 55: Key demographic indicators for China, 2005 233 Table 56: Top 10 causes of mortality in China, 2002 234 Table 57: Key economic indicators for China, 2003-06 236 Table 58: Several ministerial-level agencies have varying degrees of health authority in China 242 Table 59: Key Chinese health expenditure indicators, 2004 243 Table 60: Healthcare worker density in China is insufficient 247 Table 61: Categories of drug applications submitted to the SFDA and their data protection periods 252 Table 62: Top 25 pharmaceutical companies in China, 2006 271 Table 63: Anti-infectives were the largest ATC group by revenue in 2006 272 Table 64: Top 25 brands in China, 2006 276 Table 65: Top 25 drug molecules by sales value in China, 2006 277 Table 66: Many multinational companies have engaged in R&D in China 288 Table 67: Basic population facts for Turkey, 2005 296 Table 68: Top causes of death in Turkey in 2002 297 Table 69: Turkey - economic indicators, 2005 299 Table 70: Key health expenditure indicators for Turkey, 2004 305 Table 71: Health worker density in Turkey, 2003 306 Table 72: Maximum wholesaler and pharmacy margins in Turkey are based on a regressive scale 318 Table 73: Consumption of medicines in Turkey (million boxes per year), 2000-06 320 Table 74: Market segmentation in Turkey by ATC group spend, 2006 321 Table 75: Top 20 pharmaceutical brands in Turkey, 2006 324 Table 76: Top 20 drug manufacturers in Turkey by value, 2006 326 Table 77: Exchange rates for national currencies 362 Table 78: Segmentation of the Russian pharmaceutical market in 2005 366 Table 79: Top domestic manufacturers in Russia by sales value in 2006 367 Table 80: Top 20 drug manufacturers by pharmacy sales value in the Russian commercial market in 2005 and 2006 368 Table 81: Top 20 manufacturers on the Russian hospital segment, 2005-06 370 Table 82: Top 20 brands in the hospital segment of the Russian market in 2006 according to Aston Consulting 371 Table 83: TOP 20 drug manufacturers by DLO consumption in 2005 and 2006 373 Table 84: Top 20 brands by pharmacy sales value in the DLO segment in 2005 and 2006 374 Table 85: Top 20 drug manufacturers on the Russian market, 2006 376 Table 86: Top 20 brands on the Russian pharmaceutical market, 2006 377 Table 87: ATC group spend in Russia, 2006 378 Table 88: IMS MIDAS audit (1 of 4) 379 Table 89: IMS MIDAS audit (2 of 4) 380 Table 90: IMS MIDAS audit (3 of 4) 381 Table 91: IMS MIDAS (audit 4 of 4) 382 Figure 1: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical market in Brazil 14 Figure 2: Pharmaceutical market dynamics in Brazil: an attractive proposition for foreign companies 15 Figure 3: Retail pharmaceutical market in Brazil, 2002-2006 47 Figure 4: Comparison of market shares of different ATC groups between Brazil and the six major markets 53 Figure 5: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical market in Russia 69 Figure 6: Pharmaceutical market dynamics in Russia 70 Figure 7: The Russian healthcare system includes many bodies both at the federation and regional level 84 Figure 8: Mandatory Health Insurance Fund financing in Russia, 2007 86 Figure 9: The DLO reimbursement chain 104 Figure 10: Size and segmentation of the Russian pharmaceutical market ($ billion), 2004-2005 111 Figure 11: Top six distributors in the Russian market, 2005-2006 113 Figure 12: Advantages and disadvantages of carrying out clinical trials in Russia 163 Figure 13: Key macroeconomic factors and healthcare system characteristics influencing the pharmaceutical market in India 167 Figure 14: Pharmaceutical market dynamics in India 168 Figure 15: Maximum retail prices of controlled drugs in India are calculated using a formula 202 Figure 16: The retail pharmaceutical market in India is growing faster than the country's GDP, 2003-06 206 Figure 17: Drug distribution network in India 207 Figure 18: The market share of different ATC groups in India differs substantially from the six major markets 212 Figure 19: Advantages and disadvantages of conducting clinical trials in India 229 Figure 20: Key macroeconomic factors and healthcare system dynamics in China 231 Figure 21: Key pharmaceutical market dynamics in China 232 Figure 22: Protection of pharmaceutical products in China with or without a patent, 2006 253 Figure 23: Key steps for drug approval in China, 2006 257 Figure 24: Drug reimbursement in China 266 Figure 25: The growth rate of the Chinese hospital market is slowing down, 2002-06 267 Figure 26: The growth of the Chinese market is driven largely by growth in value not volume, 2002-06 268 Figure 27: Drug distribution channels in China, 2006 269 Figure 28: The market share of the individual ATC groups differs significantly between China and the six major markets 273 Figure 29: Revenues of all ATC groups are growing but anti-infectives are slowing down 275 Figure 30: Advantages and disadvantages of conducting clinical trials in China 291 Figure 31: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical market in Turkey 294 Figure 32: Pharmaceutical markets in Turkey 295 Figure 33: The drug approval process in Turkey is complicated and lengthy 313 Figure 34: Pharmaceutical market size in Turkey, 2002-2006 319 Figure 35: Positioning of different therapy groups on the Turkish market 322 Figure 36: The relative market shares of each ATC group differ substantially between Turkey and the six major markets, 2006 323 Figure 37: The size and segmentation of the pharmaceutical market in Russia, 2005-06 365 Figure 38: Russian pharmaceutical market, 2002-06 366 [Fade out list of tables / figures] |
||||||||||||
| Price ** (Report format): |
free of shipping costs ** IMPORTANT: All prices are net prices without taxes. Depending on the country in your billing address you have to pay sales taxes. If you have given us your billing adress, VAT No., etc. the correct total amount will be stated in the following order process. More informations on prices and taxes please find in our FAQs. |
|||||||||||
| Notice for this market research report: | * The invoice amount for this study is accounted in $ (dollar). Your bank or your credit card supplier will calculate the topical day course in your currency to you on payment. | |||||||||||
|
Further Reports of Datamonitor: Transport and Logistics Financial Deals Quarterly Roundup - Q3 2008 Next Generation Functional Food and Drinks: Opportunities in Personalized Nutrition Confectionery in Japan to 2012 Hot drinks in Italy to 2012 Sauces, dressings and condiments in Denmark to 2011 [More...] |
